The Motley Fool··Josh Kohn-LindquistTransMedics Soars 104% as Organ Transplant Monopoly Justifies Premium Valuation
TransMedics surges 104% on organ transplant dominance and 32% growth, but 56x forward earnings premium and 25% short interest raise sustainability questions for 2026.
TMDXvaluationmarket share